HDL cholesterol and cardiovascular outcomes: What is the evidence?

Current Cardiology Reports

Volumn 15, Issue 4, 2013, Pages

  Rubenfire, Melvyn ^a,b   Brook, Robert D ^a,b  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b NONE   (United States)

Author keywords

AIMHIGH; Cholesteryl ester transfer protein inhibitor; Coronary disease risk; Coronary heart disease; HDL function; HDL particles; High density lipoprotein cholesterol; Reverse cholesterol transport

Indexed keywords

BIOLOGICAL MARKER; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

BLOOD; CARDIOVASCULAR DISEASE; EVIDENCE BASED MEDICINE; HUMAN; METHODOLOGY; PARTICLE SIZE; REVIEW; TREATMENT OUTCOME;

BIOLOGICAL MARKERS; CARDIOVASCULAR DISEASES; CHOLESTEROL, HDL; EVIDENCE-BASED MEDICINE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; PARTICLE SIZE; TREATMENT OUTCOME;

MLCS; MLOWN;

EID: 84880441299     PISSN: 15233782     EISSN: 15343170     Source Type: Journal    
DOI: 10.1007/s11886-013-0349-3     Document Type: Article

References (59)

1. Gordon T, Castelli WP, Hjortland MC, et al. High density lipoprotein as a protective factor against coronary heart disease: the Framingham study. Am J Med. 1977;62:707-14. (Pubitemid 8110784)
2. The Emerging Risk Factors Collaboration. Major lipids, apolipoproteins, and risk of vascular disease. JAMA. 2009;302:1993-2000.
3. Prospective Studies collaboration. Blood cholesterol and vascular mortality by age, sex, and blood pressure: a meta-analysis of individual data from 61 prospective studies with 55, 000 vascular deaths. Lancet. 2007;370:1829-39.
4. Vergeer M, Holenboom AG, Kastelein JJP, et al. The HDL hypothesis: does high-density lipoprotein protect from atherosclerosis? J Lipid Res. 2010;51:2058-73.
5. Singh IM, Shishehbor MH, Ansell BJ. High-density lipoprotein as a therapeutic target. A systematic review. JAMA. 2007;298:786-98. (Pubitemid 47263161)
6. Ashen MD, Blumenthal RS. Low HDL cholesterol levels. N Eng J Med. 2005;353:1252-60. (Pubitemid 41345947)
7. Huxley RR, Barzi F, Lam TH, et al. Isolated low levels of highdensity lipoprotein cholesterol are associated with an increased risk of coronary heart disease. An individual participant data metaanalysis of 23 studies in the Asia-Pacific region. Circulation. 2011;142:2056-64.
8. Am S, Cannon CP, Deedwania PC, et al. Lipid levels in patients hospitalized with coronary artery disease: An analysis of 136, 905 hospitalizations in get with the guidelines. Am Heart J. 2009;157:111-7.
9. Alsheikh-Ali A, Lin J-L, Abourjaily P, et al. Prevalence of low highdensity lipoprotein cholesterol in patients with documented coronary heart disease or risk equivalent and controlled low-density lipoprotein cholesterol. Am J Cardiol. 2007;100:1499-501. (Pubitemid 350050854)
10. Cholesterol Treatment Trialists' CTT Collaboration. Efficacy and safety of more intensive lowering of LDL cholesterol: a metaanalysis of data from 170 000 participants in 26 randomized trials. Lancet. 2010;376:1670-81.
11. Baigent C, Keech A, Kearney, et al. For the Cholesterol Treatment Trialists' (CTT) Collaborators. Efficacy and safety of cholesterollowering treatment: prospective meta-analysis of data from 90, 056 participants in 14 randomised trials of statins. Lancet. 2008;371:117-25.
12. Barter P, Gotto AM, La Rosa JC, et al. HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events. N Engl J Med. 2007;357:1301-10. (Pubitemid 47481452)
13. Jafri H, Alsheikh-Ali AA, Karas RH. Meta-analysis: statin therapy does not alter the association between low levels of high-density lipoprotein cholesterol and increased cardiovascular risk. Ann Intern Med. 2010;153:800-8.
14. Ridker PM, Genest J, Boekholdt SM, et al. HDL cholesterol and residual risk of first cardiovascular events after treatment with potent statin therapy: an analysis from the JUPITER trial. Lancet. 2010;376:333-9.
15. Mora S, Glynn RJ, Boekholdt SM, et al. On-treatment non-highdensity lipoprotein cholesterol, apolipoprotein B, triglycerides, and lipid ratios in relation to residual vascular risk after treatment with potent statin therapy. J Am Coll Cardiol. 2012;59:1521-8.
16. Mora S, Wenger NK, DeMicco DA, et al. Determinants of residual risk in secondary prevention patients treated with high-versus lowdose statin therapy. The Treating to New Targets (TNT) study. Circulation. 2012;125:1979-87.
17. Chapman MJ, Ginsberg HN, Amarenco P, et al. Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management. Eur Heart J. 2011;32(11):1345-61.
18. Michos ED, Sibley CT, Baer JT, et al. Niacin and statin combination therapy for athersclerosis regression and prevention of cardiovascular disease events. J Am Coll Cardiol. 2012;59:2058-64.
19. Weissglas-Volkov D, Pajukanta P. Genetic causes of high and low serum HDL-cholesterol. J Lipid Res. 2010;51:2032-57.
20. Schaefer EJ, Lamon-Fava S, Ordovas JM, et al. Factors associated with low and elevated plasma high density lipoprotein cholesterol and apolipoprotein A-1 levels in the Framingham Offspring Study. J Lipid Res. 1994;35:871-82. (Pubitemid 24157238)
21. Rosenson RS, Brewer HB, Chapman MJ, et al. HDL Measures, particle heterogeneity, proposed nomenclature, and relationship to atherosclerotic events. Clin Chem. 2011;57(3):392-410.
22. McQueen MJ, Hawken S, Wang X, et al. Lipids, lipoproteins, and apolipoproteins as risk markers of myocardial infarction in 52 countries (the INTERHEART study): a case-control study. Lancet. 2008;372:224-33. (Pubitemid 351978112)
23. van der Steeg WA, Holme I, Boekholdt SM, et al. High-Density Lipoprotein Cholesterol, high-density lipoprotein particle size, and apolipoprotein A-I: significance for cardiovascular risk: the IDEAL and Epic-Norfolk studies. J Am Coll Cardiol. 2008;51:634-42. (Pubitemid 351186873)
24. El Harchaoui K, Arsenault B, Franssen R, et al. High-density lipoprotein particle size and concentration and coronary risk. Ann Intern Med. 2009;150:84-93.
25. Mackey RH, Greenland P, Goff DC, et al. High-density lipoprotein cholesterol and particle concentrations, carotid atherosclerosis, and coronary events: MESA (Multi-Ethnic Study of Atherosclerosis). J Am Coll Cardiol. 2012;60:508-16.
26. Navab M, Reddy ST, Lenten BJ, Fogelman AM. Nat Rev Cardiol. 2011;8(4):222-32.
27. Otocka-Kmiecik A, Mikhailidis DP, Nicholls SJ, et al. Dysfunctional HDL: a novel important diagnostic and therapeutic target in cardiovascular disease. Prog Lip Res. 2012;51:314-24.
28. Navab M, Anantharamajah GM, Reddy ST, et al. HDL as a biomarker, potential therapeutic target, and therapy. Diabetes. 2009;58(12):2711-7.
29. Rader DJ, de Goma EM. Approach to the Patient with Extremely Low HDL-Cholesterol. J Clin Endocrinol Metab. 2012;97 (10):3399-407.
30. Chiesa G, Sirtori CR. Apolipoprotein A-1 Milano: current perspectives. Curr Opin Lipidol. 2003;14:159-63. (Pubitemid 36521186)
31. Thompson A, Di Angelantonio E, Sarwar N, et al. Association of cholesterol ester transfer protein genotypes with CETP mass and activity, lipid levels, and coronary risk. JAMA. 2008;299:2777-88. (Pubitemid 351846853)
32. Vasan RS, Pencina MJ, Robins SJ, et al. Association of circulating cholesteryl ester transfer protein activity with incidence of cardiovascular disease in the community. Circulation. 2009;120:2414-20.
33. Chapman MJ, Le Goff W, Guerin M, et al. Cholesteryl ester transfer protein: at the heart of the actions of lipid-modulating therapy with statins, fibrates, niacin, and cholesteryl ester transfer protein inhibitors. Eur Heart J. 2010;31:149-64.
34. Voight B, Pelos GM, Orho-Melander M, et al. Plasma HDL cholesterol and risk of myocardial infarction: a Mendelian randomization study. Lancet. 2012;380:527-80.
35. Johannsen TH, Kamstrup PR, Andersen RV, et al. Hepatic lipase, genetically elevated high-density lipoprotein, and risk of ischemic cardiovascular disease. J Clin Endcrinol Metab. 2009;94(4):1264-73.
36. Haase CL, Tybjaerg-Hansen A, Qayyum AA, et al. LCAT, HDL Cholesterol and Ischemic Cardiovascular Disease: a Mendelian Randomization Study of HDL Cholesterol in 54, 500 individuals. J Clin Endocrinol Metab. 2012;97:E248-56.
37. Roussell MA, Kris-Etherton P. Effects of lifestyle intervention on high density lipoprotein cholesterol levels. J Clin Lipidol. 2007;1:65-73. (Pubitemid 46696623)
38. Gaziano JM, Buring JE, Breslow JL, et al. Moderate alcohol intake, increased levels of high-density lipoprotein and its subfractions, and decreased risk of myocardial infarction. N Engl J Med. 1993;329:1829-34. (Pubitemid 23360481)
39. Marmllot P, Munoz J, Patel S, et al. Long-term ethanol consumption impairs reverse cholesterol transport function of high-density lipoproteins by depleting high-density lipoprotein sphingomyelin both in rats and in humans. Metab Clin Exper. 2007;56:947-53. (Pubitemid 46890978)
40. Coronary Drug Project Research Group. Clofibrate and niacin in coronary heart disease. JAMA. 1975;231:360-81.
41. Canner PL, Berge KG, Wenger NK, et al. Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin. J Am Coll Cardiol. 1986;8(6):1245-55. (Pubitemid 17208898)
42. Canner PL, Furberg CD, McGovern ME. Benefits of niacin in patients with versus without the metabolic syndrome and healed myocardial infarction (from the Coronary Drug Project). Am J Cardiol. 2006;97(4):477-9. (Pubitemid 43190034)
43. Rosenson RS. Antiatherothrombotic effects of nicotinic acid. Atherosclerosis. 2003;171:87-96. (Pubitemid 37464633)
44. Brown GB, Zhao XQ, Chait A, et al. Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. N Engl J Med. 2001;345(1583-92):60-4. (Pubitemid 33126837)
45. Cashin-Hemphill L, Mack WJ, Pogoda JM, et al. Beneficial effects of colestipol-niacin on coronary atherosclerosis. A 4-year followup. JAMA. 1990;264(23):3013-7.
46. Brown G, Albers JJ, Fisher LD, et al. Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B. N Engl J Med. 1990;323:1289-98. (Pubitemid 20364735)
47. Blankenhorn DH, Selzer RH, Crawford DW, et al. Beneficial effects of colestipol-niacin therapy on the common carotid artery. Two-and four-year reduction of intima-media thickness measured by ultrasound. Circulation. 1993;88:20-8. (Pubitemid 23195428)
48. Taylor AJ, Sullenberger LE, Lee HJ, et al. Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol (ARBITER) 2: a double-blind, placebo-controlled study of extended-release niacin on atherosclerosis progression in secondary prevention patients treated with statins. Circulation. 2004;110:3512 17.
49. Whitney EJ, Krasuski RA, Personius BE, et al. A randomized trial of a strategy for increasing high-density lipoprotein cholesterol levels: effects on progression of coronary heart disease and clinical events. Ann Intern Med. 2005;142(2):95-104.
50. Villines TC, Stanek EJ, Devine PJ, et al. Michael Miller, The ARBITER 6-HALTS Trial. J Am Coll Cardiol. 2010;55:2721-6.
51. Shlipak MG, Chaput LA, Vittinghoff E, et al. Lipid changes on hormone therapy and coronary heart disease events in the Heart and Estrogen/progestin Replacement Study (HERS). Am Heart J. 2003;146(5):870-5. (Pubitemid 37378577)
52. Barter PJ, Caulfield M, Eriksson M, et al. Effects of torcetrapib in patients at high risk for coronary event. N Engl J Med. 2007;357 (21):2109-22. (Pubitemid 350146106)
53. Cannon CP. High-density lipoprotein cholesterol as the holy grail. JAMA. 2011;306(19):2153-5.
54. Schwartz GG, Olsson AG, Abt M, et al. Effects of dalcetrapib in patients with a recent acute coronary syndrome. N Engl J Med. 2012. doi:10.1056/ NEJMoa1206797.
55. The Aim-High Investigators. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N Engl J Med. 2011;365:2255-67.
56. The AIM-HIGH investigators. The role of niacin in raising high-density lipoprotein cholesterol to reduce cardiovascular events in patients with atherosclerotic cardiovascular disease and optimally treated low-density lipoprotein cholesterol: rationale and study design. The atherothrombosis intervention in metabolic syndrome with lowHDL/high triglycerides: impact on global health outcomes (AIM-HIGH). Am Heart J. 2011;161:471-477.e2.
57. Lamon-Fava S, Diffenderfer MR, Barrett PH, et al. Extended release niacin alters the metabolism of plasma apolipoprotein (Apo) A-I and ApoB-containing lipoproteins. Arterioscler Thromb Vasc Biol. 2008;28(9):1672-8.
58. Green PS, Vaisar T, Pennathur S, et al. Combined statin and niacin therapy remodels the high-density lipoprotein proteome. Circulation. 2008;118(12):1259-67.
59. Pedersen TR, Faergeman O, Kastelein JJ, et al. High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial. JAMA. 2005;294(19):2437-45. (Pubitemid 41627921)